Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.14
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$35.03M
Enterprise ValueC$15.56M
Total Cash (Recent Filing)C$7.02M
Total Debt (Recent Filing)C$295.68K
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,487,120
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage and very low absolute debt reduce near-term balance-sheet stress for a pre-revenue biotech. This strengthens financial flexibility to fund multi-year clinical programs and lowers bankruptcy risk, an important structural advantage during long R&D cycles.
Free Cash Flow ImprovingAn improving free-cash-flow trend, even from negative levels, signals progress slowing cash burn and better operational discipline. For an R&D-stage drug developer, reduced cash outflow improves runway and lessens immediate financing reliance over the next several quarters.
Focused Therapeutic StrategyClear strategic focus on psychedelic-derived therapeutics targets a structurally expanding mental-health market and allows concentrated R&D expertise. A focused pipeline can create durable competitive advantages if clinical progress is achieved and IP is secured.
Bears Say
Near-zero RevenueEffectively zero trailing revenue indicates the company is not yet commercialized. Without revenue diversification or a clear path to customers, the firm remains dependent on financing and milestones, limiting durable cash generation and scaling prospects over months.
Large Operating LossesSizeable recurring losses reflect sustained R&D and operating spend without offsetting commercial income. Persistent negative profitability erodes reserves and requires repeated capital raises, which can dilute shareholders and constrain long-term investment flexibility.
Ongoing Cash Burn And Funding RelianceContinued negative operating and free cash flow points to structural cash burn that necessitates external financing or balance-sheet actions. Reliance on capital markets increases execution risk and may force trade-offs in R&D timelines or program prioritization.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.02 and its highest was C$0.14 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$35.03M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 6 days.
How were Lobe Sciences’s earnings last quarter?
Currently, no data Available
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 269,487,120 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---